Cutacelan

Quick links to important sections

Cutacelan

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cutacelan

What is Cutacelan? A Factual Overview

This section defines the medicinal identity, composition, and general role of the topical preparation known commercially as Cutacelan, establishing foundational facts without discussing usage instructions, safety, or commercial details.

Property Description
Active ingredient Azelaic Acid
Form Cream, Gel, Topical preparation
Pharmacological Class Anti-acne agent, Dermatological agent
Route of Administration Topical/Dermal
Origin Synthetic derivative of a Dicarboxylic Acid

Identity and Pharmacological Classification

The core medicinal substance in Cutacelan is Azelaic Acid, a compound chemically categorized as a saturated, nine-carbon Dicarboxylic Acid. It is classified as an Anti-acne agent within the family of Dermatological Agents. Though found naturally in grains like wheat and barley, the active ingredient used in medicine is typically synthesized to ensure pharmaceutical-grade purity and consistency.

Pharmacological studies have described Azelaic Acid's activity, positioning it as a key topical solution because of its multi-functional properties, which include concurrent anti-inflammatory and antimicrobial actions.


Composition, Origin, and Topical Form

Azelaic Acid is formulated exclusively for topical administration, delivering the active ingredient directly to the skin surface. The drug is available as a monotherapy, with Azelaic Acid being the sole medicinal compound, presented either as a cream or an aqueous gel. The use of a dermal route ensures the active substance achieves maximum therapeutic concentration locally while minimizing systemic exposure.


General Therapeutic Role and Core Benefit

The overarching therapeutic role of this preparation is based on its combined antimicrobial, anti-inflammatory, and keratolytic (pore-clearing) properties. This multi-action profile enables it to address several components of persistent skin issues simultaneously.

The core benefit is derived from its ability to concurrently target bacterial proliferation, calm associated redness and irritation, and assist in the normalization of skin cell turnover. This combined approach is used to provide general relief from the inflammatory components of common skin irritations.

What side effects are possible with Cutacelan?

Possible side effects and safety information for Cutacelan (Azelaic Acid)

The official safety profile for Azelaic Acid is predominantly characterized by localized reactions at the application site, as documented in government regulatory sources. These reactions are typically categorized by frequency based on clinical study data.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Very Common (Likely to affect more than 1 in 10 people) Application site burning, pruritus (itching), erythema (redness), and pain.
Common (Likely to affect up to 1 in 10 people) Application site exfoliation, dryness, discolouration, irritation, and paraesthesia (tingling).
Uncommon (Likely to affect up to 1 in 100 people) Application site dermatitis, discomfort, oedema, seborrhoea, acne, and skin depigmentation.

Time-Related and Serious Safety Characteristics

Local skin irritation, including burning and pruritus, is most likely to occur during the first few weeks of treatment and is officially documented to regress in the course of continued therapy. This establishes a predictable pattern for the most frequent adverse reactions.

Serious Adverse Reactions are rare but officially documented, including hypersensitivity reactions (classified under Immune System disorders) such as angioedema (rapid swelling), facial swelling, and dyspnoea (shortness of breath). Worsening of asthma has also been reported through surveillance data.

Specific Safety Considerations

The official labeling notes that contact with the eyes, mouth, and other mucous membranes must be avoided. Additionally, regulatory documents advise that patients with a dark complexion should be monitored for signs of hypopigmentation (skin color lightening). Safety and efficacy have not been established in the pediatric population under 12 years of age.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cutacelan (Azelaic Acid) overdose addresses the potential for excessive topical use and accidental oral ingestion. Due to the product's formulation for dermal application, systemic absorption is limited, and acute overdose is generally not expected to be associated with significant systemic toxicity. Regulatory documents classify the acute risk as low, meaning life-threatening complications are not explicitly documented.

Excessive application to the skin may result in localized symptoms of skin irritation. However, the mandatory regulatory guidance focuses on the risk of accidental oral ingestion. In this circumstance, urgent medical attention must be sought immediately. Contacting emergency services or a poison control center is the required first action.

In the management of suspected overdose, the official labeling states that no specific antidote is known for the active ingredient. Consequently, medical intervention is focused entirely on providing symptomatic and supportive treatment to manage the patient's clinical presentation. General observation and monitoring may be required following oral ingestion. No specific population-based considerations are documented in the official overdose sections.

Therapeutic Uses of Cutacelan

What Cutacelan Treats: Main Uses and Benefits

Cutacelan (Azelaic Acid) is generally applied in contexts involving inflammatory or irritative states of the skin, relevant across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms in the dermatological field.

Treating Inflammatory Conditions

This medication is commonly used to help with the symptomatic management of acne vulgaris and papulopustular rosacea, and may assist in addressing residual skin discoloration. Its use focuses on symptoms related to physical discomfort, such as inflammatory lesions, associated redness, and clogged pores. The application of this medication may assist with easing patient distress during periods of heightened symptoms, and supports day-to-day comfort.

“The therapeutic approach is relevant for managing symptoms that interfere with daily comfort, and may be part of symptomatic management when symptoms become more noticeable.”


Quick Fact: Relief for Inflammatory Blemishes and Redness

This medication is often used when symptoms intensify, providing support that helps ease the overall symptom burden, particularly related to the papules, pustules, and facial erythema characteristic of its primary indications. Its use supports the patient during difficult episodes by contributing to easing the overall symptom load.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility profile for Cutacelan (Azelaic Acid) is strictly defined by government regulatory documents based on patient age and physiological status.

Eligibility Group Regulatory Status
Contraindicated Populations Individuals with a documented hypersensitivity or allergy to the active substance (Azelaic Acid) or any of the inactive ingredients must not use the medicine.
Age Eligibility Use is established for adults and adolescents 12 years old and older. Use is not established or recommended for children under the age of 12 due to insufficient data.
Pregnancy & Lactation Use during pregnancy is conditional; permitted only if clearly necessary due to limited human data. Use during lactation is also conditional, with caution advised, specifically avoiding application to the breast area.
Organ Function No specific restrictions or dosage adjustments are documented in regulatory labeling for the topical formulation regarding renal or hepatic impairment.

Official Eligibility Statements:

  • Must Not Use (Contraindicated): Individuals with known hypersensitivity to the components.
  • Allowed (Established Use): Adults and adolescents aged 12 years and older.
  • Restricted/Conditional Use: Children under 12 years of age; Pregnant and breastfeeding individuals.

The regulatory framework defines eligibility based on absolute exclusion for hypersensitivity and inclusion based on a minimum age of 12 years for use. Conditional use is applied to pregnant and breastfeeding populations, noting the minimal systemic absorption of the topical product. No specific eligibility limitations are placed on patients with renal or hepatic impairment for the topical formulation.

What should I know about interactions with other medicines?

The official interaction profile for Cutacelan (Azelaic Acid) is characterized by its low potential for systemic drug-drug interactions. This characteristic is supported by the drug's pharmacokinetic behavior following topical administration, which results in minimal systemic absorption; regulatory data indicates only a small percentage of the applied dose reaches the bloodstream.

This low systemic exposure substantially limits the potential for the medicine to alter the plasma concentrations of co-administered systemic medicinal products, or for other medicines to alter the systemic exposure of Azelaic Acid. Furthermore, metabolic interactions are not expected, as the active ingredient is primarily metabolized via beta-oxidation into shorter-chain dicarboxylic acids and does not interact with the cytochrome P450 (CYP450) enzyme system.

Based on these regulatory assessments, there are no formal contraindicated combinations with other systemic medicines documented in official labeling. No mandatory timing separation rules are listed for co-administering Cutacelan with systemic medications. Similarly, the official prescribing information does not document systemic interactions with food, alcohol, herbal products, or supplements, and contains no specific population-based interaction cautions related to conditions such as hepatic impairment.

Mechanism of Action

The action of Azelaic Acid involves a multi-functional pharmacological profile that concurrently targets three distinct biological processes: cell proliferation, microbial activity, and innate immune response.

Modulation of Epithelial Cell Turnover

The molecule acts as a reversible inhibitor of the excessive proliferation and abnormal differentiation of keratinocytes, the cells lining the hair follicle. This mechanism modulates the rate of epithelial cell shedding, which contributes to limiting the formation of cellular plugs (microcomedones) and reducing follicular obstruction.


Modulation of Innate Inflammatory Signaling

Azelaic Acid modulates several key pathways involved in the innate immune response. It inhibits the enzyme Kallikrein 5 (KLK5), which reduces the concentration of the pro-inflammatory peptide LL-37, while also acting as a scavenger of Reactive Oxygen Species (ROS). This combined action contributes to a dampening of the local immune response, limiting the downstream physiological effects of inflammation.


Impairment of Bacterial Homeostasis

The drug exerts a bacteriostatic effect on key skin bacteria, notably Cutibacterium acnes, by interfering with their internal processes. It inhibits microbial protein synthesis and disrupts the bacterial cell's transmembrane pH gradient, which collectively results in a decrease in the release of bacterial byproducts and a lowering of the microbial population density.

Dosage and Administration Information

How to Use Cutacelan: Administration Guidelines

Cutacelan (azelaic acid topical cream/gel) is strictly for topical use on the skin, as directed by prescribing information. It must not be taken by mouth or applied to the eyes, mouth, or other mucous membranes.

Administration Scope

Guideline Entity Instruction
Dosing Schedule Apply a thin layer to the affected area(s).
Frequency Twice daily (BID), typically once in the morning and once in the evening.
Route of Administration Topical only (dermatologic use).
Age Rules Standard dosing is used for adults and adolescents 12 years and older. Safety and efficacy are not established in younger children.
Missed Dose If a dose is missed, apply it as soon as possible, but skip it and continue the regular schedule if it is almost time for the next application. Do not apply a double amount.

Procedural Steps

Correct application requires specific preparation and handling:

  1. Preparation: Wash the affected area thoroughly with a mild soap or soapless cleansing lotion and gently pat the skin dry before each application.
  2. Application: Gently but thoroughly massage a thin layer of the cream or gel into the affected area(s).
  3. Hand Hygiene: Wash your hands immediately after applying the medicine.

Patients should avoid using occlusive dressings (bandages or wrappings) over the treated skin. Cosmetics or moisturizers may be applied after the medicine has dried. The duration of use is variable, and the need for continued treatment should be reassessed periodically by a healthcare provider.

Recent Clinical Evidence

Cutacelan: Recent Clinical Evidence

The official research base for Cutacelan (Azelaic Acid) relies mainly on high-quality studies known as Randomized Controlled Trials (RCTs) and systematic reviews. These trials typically compare the topical preparation against an inactive base (a vehicle) or against other established topical treatments to evaluate outcomes.


Research Evidence for Acne Vulgaris and Rosacea

Research has examined the topical use for mild-to-moderate inflammatory acne in adults and adolescents. Studies monitored several outcomes, including the change in the number of both inflamed lesions (papules and pustules) and non-inflamed blockages. Pivotal trials reported outcomes that included changes in lesion counts and overall clinical assessment scores compared to an inactive base.

Similarly, evidence for papulopustular rosacea is rooted in controlled trials enrolling adults dealing with inflammatory bumps and pimples. Studies examined endpoints like changes in inflammatory lesion numbers and facial redness (erythema). Trials reported outcomes that included changes in lesion counts and patterns in global assessment scores. A key research point is that it is not fully established how the preparation affects the underlying process in rosacea.


Overview of Follow-up and Research Gaps

Core efficacy trials for both acne and rosacea typically involve monitoring over a defined time interval, most commonly 12 weeks. While this provides initial data, research indicates that the long-term effects are not fully established regarding the durability of the response. For pigmentary issues like melasma, research involves comparative trials over longer periods, with findings that described patterns which varied across study protocols.

Studies have primarily focused on standard adult and adolescent populations. Consequently, evidence for certain groups remains insufficient, such as large-scale data for older adults with rosacea, or in patients with specific comorbid skin conditions. This means research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Cutacelan (FAQ)


Q: How quickly can I expect to see results when using Cutacelan?

Studies and official information indicate that for acne, noticeable therapeutic improvement may begin to be seen after the first 4 to 6 weeks of treatment. For both acne and rosacea, the full benefit is typically evaluated in clinical trials conducted over 12 weeks of continuous use.


Q: What is the longest continuous time people typically use Cutacelan?

Regulatory information indicates that the need for continued therapy should be reassessed periodically by a healthcare provider. While initial clinical trials usually monitor outcomes over 12 weeks, the decision to continue the treatment long-term is based on ongoing assessment by a health professional.


Q: Can Cutacelan be used effectively with a gentle cleanser and moisturizer?

Official administration guidelines advise washing the affected area with a mild soap or soapless cleansing lotion and gently patting the skin dry before applying Cutacelan. After the medication has dried, it is generally acceptable to apply cosmetics and moisturizers. For individuals with rosacea, regulatory documents note that products containing alcohol, abrasives, or strong peeling agents may need to be avoided, and this should be discussed with a healthcare provider.


Q: Is it safe to use makeup over Cutacelan?

Yes, official product information states that cosmetics, which includes makeup, may be applied to the skin after the Cutacelan cream or gel has fully dried.


Q: Is it safe to use Cutacelan while trying to conceive?

Due to minimal systemic absorption, the risk to an unborn child is generally considered low. However, because limited human data is available, the product information indicates that the use of the medicine is dependent on a healthcare provider determining that the potential benefit outweighs any potential risk.


Q: Does Cutacelan affect the effectiveness of topical antibiotics?

Regulatory documents state that interactions with other systemic (oral) medicines are not expected due to the minimal absorption of Cutacelan into the bloodstream. However, because data on topical-topical interactions is limited, all topical products should be disclosed to the prescriber.


Q: Does applying more Cutacelan make it work faster?

The product information specifies that only a thin layer of the cream or gel should be applied to the affected areas. Using excessive amounts is not advised, as this may increase the risk of local skin irritation and is not shown to improve effectiveness.


Q: Can Cutacelan worsen acne before it gets better?

While regulatory documents do not specifically list an initial worsening of the condition itself, it is very common to experience local side effects like burning, itching, or peeling during the first few weeks of treatment. These common irritations are documented to typically decrease in severity with continued use.


Q: What are the signs that Cutacelan is starting to work?

Clinical trials measured efficacy based on a reduction in the number of inflamed lesions, such as papules and pustules. Therefore, signs of the medication working include a gradual decrease in inflammatory bumps and an improvement in the overall appearance of the treated skin area.


Q: Does Cutacelan help with dark spots or hyperpigmentation?

While the primary indications for Cutacelan are acne and rosacea, the active ingredient, azelaic acid, has been studied in the treatment of some pigmentary issues. Separately, patients with dark complexions are monitored for hypopigmentation (skin lightening) as a potential side effect.


Q: Can Cutacelan be used for treating acne and rosacea at the same time?

Cutacelan is officially indicated for the topical treatment of both acne vulgaris and papulopustular rosacea. The decision for concurrent use and appropriate application should be guided by a healthcare professional.


Q: Does Cutacelan help with reducing redness associated with rosacea?

Yes, regulatory documents indicate that the Azelaic Acid gel formulation is specifically approved for treating the inflammatory papules, pustules, and the associated erythema (redness) of mild-to-moderate rosacea.


Q: Why do some people say Cutacelan helps with oiliness?

The drug’s mechanism of action includes the normalization of epithelial cell turnover, which is a process related to the factors that cause oily skin. Although it is not officially indicated as a treatment for oiliness, this mechanism may contribute to a perceived reduction in skin oiliness.


Q: Does the efficacy of Cutacelan vary by skin tone or type?

Clinical trials have not shown differences in efficacy or safety based on age, sex, race, or ethnicity. However, for patients with a dark complexion, monitoring for hypopigmentation (skin color lightening) is noted as a necessary precaution.


Q: Do food or dietary changes affect how Cutacelan works?

Since very little of the topically applied medication is absorbed into the bloodstream, interactions with food or dietary changes are not expected. Avoiding known triggers like spicy foods or hot drinks may be relevant for managing rosacea symptoms, independent of the medication.


Q: What is the likelihood of developing an allergic reaction to Cutacelan?

Serious adverse reactions, including hypersensitivity (allergic reaction), are considered rare. These reactions, such as rapid swelling (angioedema) or worsening of asthma, have been reported through post-marketing surveillance rather than in large clinical trials.


Q: Why is consistency important when using Cutacelan for chronic conditions?

The therapeutic benefits for chronic conditions like acne and rosacea are established based on consistent application over a specific duration. Clinical studies confirm that adherence to the prescribed, regular schedule is necessary to achieve and maintain the full clinical improvement.


Q: Can Cutacelan be used on sensitive or compromised skin barriers?

The product is generally well-tolerated, but common adverse reactions include burning and irritation. If pronounced local irritation develops, official safety documents state that the patient may need to temporarily reduce the frequency of application or discontinue use, and a physician should be consulted.


Q: How should I apply Cutacelan for maximum absorption?

For proper application, the affected area should be thoroughly washed with a mild cleanser and gently patted dry. A thin layer of the cream or gel is to be thoroughly massaged into the affected skin area, according to the official administration guidelines.


Q: Are there any long-term studies on the safety of Cutacelan?

The core efficacy trials typically monitored patients for up to 12 weeks. While long-term safety data from extended clinical trials are not fully established, continuous post-marketing surveillance tracks and records the occurrence of rare, serious adverse events.

How should Cutacelan be stored and disposed of?

Storage and Disposal Requirements for Cutacelan (Azelaic Acid Topical)

Cutacelan must be stored at Controlled Room Temperature, generally between 15 C and 30 C (59 F and 86 F). The product must be strictly kept from freezing and stored away from excessive heat, moisture, and direct light.

Handling and Stability

The medication must be kept in its closed container. Once the tube is opened, the in-use shelf life is limited; any unused product must be discarded after a specific period, such as six months, as defined by the official labeling. As a mandatory requirement, the medicine must be kept out of the reach and sight of children.

Disposal

Unused or expired Cutacelan should be disposed of via a community drug take-back program. If this is not available, the product should be mixed with an undesirable substance, placed in a sealed bag, and discarded with household trash. Do not flush the medicine down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cutacelan found in:

A-Z Index: